<DOC>
	<DOCNO>NCT00760084</DOCNO>
	<brief_summary>The purpose study provide decitabine patient Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) complete participation per protocol DACO-018 study .</brief_summary>
	<brief_title>Trial Decitabine Patients With Acute Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>The objective trial : - To generate additional information overall safety profile , - To generate safety information hepatically renally impaired patient , appropriate , - To generate safety information patient also take concomitant medication and/or therapy without trial restriction decitabine administer dose 20 mg/m² 1-hour intravenous infusion 5 consecutive day every 4 week patient MDS AML ( ≥ 30 % blast ) . The purpose open-label , expanded-access trial provide decitabine patient AML MDS complete participation per protocol DACO-018 study continuation treatment decitabine indicate , per opinion investigator . In order continue treatment decitabine , minimum , must disease progression patient participate DACO-018 trial period patient discontinue DACO-018 study enter trial . Patients must enroll trial within 8 week discontinue DACO-018 study receive chemotherapy disease interim period . Decitabine administer dose 20 mg/m² 1-hour intravenous infusion 5 consecutive day every 4 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Must sign Institutional Review Board ( IRB ) approve informed consent form , indicate his/her awareness investigational nature decitabine potential hazard prior initiation studyspecific procedure treatment . 2 . Must one following : MDS ( de novo secondary ) fit recognize FrenchAmericanBritish classification OR chronic myelomonocytic leukemia ( WBC &lt; 12,000/μL ) AND International Prognostic Scoring System score ≥1.5 determine complete blood count , bone marrow assessment bone marrow cytogenetics within 30 day study entry OR AML ( ≥ 30 % bone marrow blast ) , except M3 acute promyelocytic leukemia . 3 . Must age 18 year old . 4 . Must complete participation per protocol MGI PHARMA DACO018 decitabine trial . 5 . Must enroll trial 8 week discontinuation MGI PHARMA DACO018 trial . 6 . Must recover toxic effect prior therapy . 1 . Must active malignancy , basal squamous cell skin carcinoma . 2 . Must receive period discontinuation DACO018 enrollment trial chemotherapy agent , include investigational agent , disease . 3 . Must evidence significant clinical disorder laboratory find make undesirable patient participate trial , discretion principal investigator . 4 . Must pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Decitabine</keyword>
</DOC>